CeriBell (NASDAQ:CBLL) Hits New 52-Week Low - What's Next?

CeriBell (NASDAQ:CBLL - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $13.00 and last traded at $17.88, with a volume of 589 shares trading hands. The stock had previously closed at $18.44.

Analysts Set New Price Targets

CBLL has been the subject of a number of research analyst reports. LADENBURG THALM/SH SH initiated coverage on CeriBell in a research report on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company. Canaccord Genuity Group restated a "buy" rating and issued a $33.00 price objective on shares of CeriBell in a report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $32.50.

CeriBell Price Performance

The firm has a 50 day simple moving average of $21.04.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The company had revenue of $18.53 million during the quarter, compared to analysts' expectations of $17.55 million. Sell-side analysts anticipate that CeriBell will post -2.46 EPS for the current year.

Remove Ads

Institutional Investors Weigh In On CeriBell

Institutional investors have recently bought and sold shares of the business. Legal & General Group Plc purchased a new stake in shares of CeriBell in the fourth quarter worth approximately $32,000. Summit Investment Advisors Inc. purchased a new position in shares of CeriBell during the 4th quarter valued at $33,000. Tower Research Capital LLC TRC acquired a new position in shares of CeriBell in the fourth quarter worth $37,000. BNP Paribas Financial Markets purchased a new stake in shares of CeriBell during the fourth quarter worth $43,000. Finally, PNC Financial Services Group Inc. purchased a new position in CeriBell in the fourth quarter valued at about $47,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.